Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
Empirical Formula (Hill Notation):
C29H26ClFN4O4S
CAS Number:
Molecular Weight:
581.06
NACRES:
NA.77
UNSPSC Code:
12352200
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
Product Name
Lapatinib, ≥98% (HPLC)
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
2-8°C
SMILES string
CS(=O)(CCNCC1=CC=C(C2=CC=C3N=CN=C(C3=C2)NC4=CC=C(C(Cl)=C4)OCC5=CC=CC(F)=C5)O1)=O
InChI
1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)
InChI key
BCFGMOOMADDAQU-UHFFFAOYSA-N
Gene Information
human ... EGFR(1956), ERBB2(2064)
Biochem/physiol Actions
Lapatinib acts as a dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR/ErbB1) and human epidermal growth factor receptor 2 (HER2/ErbB2). It competes for its binding site on the tyrosine kinase domain with adenosine triphosphate (ATP). Lapatinib mediates has been studied in vitro in the inhibition of cell growth as well as and apoptosis induction in several human cancer cells such as breast, lung, vulva, gastric, and head and neck cancer.
Still not finding the right product?
Explore all of our products under Lapatinib
signalword
Warning
hcodes
Hazard Classifications
Aquatic Chronic 4 - Eye Irrit. 2 - Lact.
Storage Class
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Lapatinib in breast cancer
Bilancia D, et al.
Annals of Oncology, 18, vi26-vi30 (2007)
Sharad Verma et al.
PloS one, 13(2), e0190942-e0190942 (2018-02-02)
HER-2 belongs to the human epidermal growth factor receptor (HER) family. Via different signal transduction pathways, HER-2 regulates normal cell proliferation, survival, and differentiation. Recently, it was reported that MCF10A, BT474, and MDA-MB-231 cells bearing the HER2 K753E mutation were
Egle Avizienyte et al.
The Biochemical journal, 415(2), 197-206 (2008-07-01)
Recent clinical data indicates that the emergence of mutant drug-resistant kinase alleles may be particularly relevant for targeted kinase inhibitors. In order to explore how different classes of targeted therapies impact upon resistance mutations, we performed EGFR (epidermal-growth-factor receptor) resistance
Global Trade Item Number
| SKU | GTIN |
|---|---|
| SML2259-10MG | 04061835504930 |
| SML2259-50MG | 04061835504947 |
